Birth characteristics and risk of colorectal cancer: a study among Swedish twins

Type-2 diabetes increases the risk of colorectal cancer, and is also associated with low birth weight. However, we found no evidence of associations between birth characteristics and risk of colorectal cancer (m=248) among Swedish twins

Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer

Objective: Reduced diversity at Human Leukocyte Antigen (HLA) loci may adversely affect the host's ability to recognize tumor neoantigens and subsequently increase disease burden. We hypothesized that increased heterozygosity at HLA loci is associated with a reduced risk of developing colorectal cancer (CRC). Methods: We imputed HLA class I and II four-digit alleles using genotype data from a population-based study of 5,406 cases and 4,635 controls from the Molecular Epidemiology of Colorectal Cancer Study (MECC). Heterozygosity at each HLA locus and the number of heterozygous genotypes at HLA class -I (A, B, and C) and HLA class -II loci (DQB1, DRB1, and DPB1) were quantified. Logistic regression analysis was used to estimate the risk of CRC associated with HLA heterozygosity. Individuals with homozygous genotypes for all loci served as the reference category, and the analyses were adjusted for sex, age, genotyping platform, and ancestry. Further, we investigated associations between HLA diversity and tumor-associated T cell repertoire features, as measured by tumor infiltrating lymphocytes (TILs; N=2,839) and immunosequencing (N=2,357). Results: Individuals with all heterozygous genotypes at all three class I genes had a reduced odds of CRC (OR: 0.74; 95% CI: 0.56-0.97, p= 0.031). A similar association was observed for class II loci, with an OR of 0.75 (95% CI: 0.60-0.95, p= 0.016). For class-I and class-II combined, individuals with all heterozygous genotypes had significantly lower odds of developing CRC (OR: 0.66, 95% CI: 0.49-0.87, p= 0.004) than those with 0 or one heterozygous genotype. HLA class I and/or II diversity was associated with higher T cell receptor (TCR) abundance and lower TCR clonality, but results were not statistically significant. Conclusion: Our findings support a heterozygote advantage for the HLA class-I and -II loci, indicating an important role for HLA genetic variability in the etiology of CRC

Genome of the Avirulent Human-Infective Trypanosome—Trypanosoma rangeli

Background: Trypanosoma rangeli is a hemoflagellate protozoan parasite infecting humans and other wild and domestic mammals across Central and South America. It does not cause human disease, but it can be mistaken for the etiologic agent of Chagas disease, Trypanosoma cruzi. We have sequenced the T. rangeli genome to provide new tools for elucidating the distinct and intriguing biology of this species and the key pathways related to interaction with its arthropod and mammalian hosts.  Methodology/Principal Findings: The T. rangeli haploid genome is ,24 Mb in length, and is the smallest and least repetitive trypanosomatid genome sequenced thus far. This parasite genome has shorter subtelomeric sequences compared to those of T. cruzi and T. brucei; displays intraspecific karyotype variability and lacks minichromosomes. Of the predicted 7,613 protein coding sequences, functional annotations could be determined for 2,415, while 5,043 are hypothetical proteins, some with evidence of protein expression. 7,101 genes (93%) are shared with other trypanosomatids that infect humans. An ortholog of the dcl2 gene involved in the T. brucei RNAi pathway was found in T. rangeli, but the RNAi machinery is non-functional since the other genes in this pathway are pseudogenized. T. rangeli is highly susceptible to oxidative stress, a phenotype that may be explained by a smaller number of anti-oxidant defense enzymes and heatshock proteins.  Conclusions/Significance: Phylogenetic comparison of nuclear and mitochondrial genes indicates that T. rangeli and T. cruzi are equidistant from T. brucei. In addition to revealing new aspects of trypanosome co-evolution within the vertebrate and invertebrate hosts, comparative genomic analysis with pathogenic trypanosomatids provides valuable new information that can be further explored with the aim of developing better diagnostic tools and/or therapeutic targets

Birthweight and mortality in adulthood: a systematic review and meta-analysis

Background: small birth size may be associated with increased risk of cardiovasculardiseases (CVD), whereas large birth size may predict increasedrisk of obesity and some cancers. The net effect of birth size onlong-term mortality has only been assessed in individual studies,with conflicting results.Methods: the Meta-analyses of Observational Studies in Epidemiology(MOOSE) guidelines for conducting and reporting meta-analysisof observational studies were followed. We retrieved 22 studiesthat assessed the association between birthweight and adult mortalityfrom all causes, CVD or cancer. The studies were systematicallyreviewed and those reporting hazard ratios (HRs) and 95%confidence intervals (95% CIs) per kilogram (kg) increase in birthweightwere included in generic inverse variance meta-analyses.Results: for all-cause mortality, 36 834 deaths were included and the resultsshowed a 6% lower risk (adjusted HR¼0.94, 95% CI: 0.92–0.97) perkg higher birthweight for men and women combined. For cardiovascularmortality, the corresponding inverse association was stronger(HR¼0.88, 95% CI: 0.85–0.91). For cancer mortality, HR per kghigher birthweight was 1.13 (95% CI: 1.07–1.19) for men and 1.04(95% CI: 0.98–1.10) for women (Pinteraction¼0.03). Residual confoundingcould not be eliminated, but is unlikely to account forthe main findings.Conclusion: these results show an inverse but moderate association of birthweightwith adult mortality from all-causes and a stronger inverseassociation with cardiovascular mortality. For men, higherbirthweight was strongly associated with increased risk of cancerdeaths. The findings suggest that birthweight can be a useful indicatorof processes that influence long-term health